Grant: Strategic Projects - Group
McMaster University
$96,500.00
MMP inhibitor modification of IOL's to inhibit posterior capsule opacification
EF 2007-08
Résumé
Loss of transparency of the lens or cataract is the leading cause of blindness in the world despite the availability of effective surgery in developed countries. Secondary cataract, or posterior capsule opacification (PCO), remains the major complication of modern cataract surgery with intraocular lens implantation. In PCO, the lens epithelial cells (LECs) which remain within the capsule after cataract surgery are triggered by unknown signals to proliferate and migrate to the posterior lens capsule. A proportion of these cells then undergo a transition into plaques which results in the opacification of the lens. The resultant PCO develops in between 20 and 40% of patients to such an extent that secondary vision loss occurs which requires further corrective surgery. While the development of intraocular lenses with sharp edges has reduced the incidence of PCO requiring corrective surgery, perhaps by delaying its development, the problem is far from being eradicated. The regulation of the processes involved in PCO is derived from the signals that the cells receive from their environment, including the cells themselves, or other ocular tissues. Of particular interest are Matrix Metalloproteinases (MMPs) which have been shown to contribute significantly to the cellular transition resulting in PCO. The current project focuses on harnessing this biology in order to limit or eradicate PCO associated with cataract surgery by delivery of MMP-inhibitors to any remaining cells. Other potential ophthalmic applications of MMP inhibiting polymers and surfaces such as in corneal wound healing will also be examined.
Programme
Strategic Projects - Group
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
321946-2005
Name nom
Sheardown, Heather
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2005
Award amount
96500
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1001
Committee name en
Strategic Projects Selection Panel - Biosciences A
Committee name fr
Comité de sélection des projets stratégiques - biosciences A
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
3
Nb partie
3
Application title
MMP inhibitor modification of IOL's to inhibit posterior capsule opacification
Keyword
NA
Application summary
Loss of transparency of the lens or cataract is the leading cause of blindness in the world despite the availability of effective surgery in developed countries. Secondary cataract, or posterior capsule opacification (PCO), remains the major complication of modern cataract surgery with intraocular lens implantation. In PCO, the lens epithelial cells (LECs) which remain within the capsule after cataract surgery are triggered by unknown signals to proliferate and migrate to the posterior lens capsule. A proportion of these cells then undergo a transition into plaques which results in the opacification of the lens. The resultant PCO develops in between 20 and 40% of patients to such an extent that secondary vision loss occurs which requires further corrective surgery. While the development of intraocular lenses with sharp edges has reduced the incidence of PCO requiring corrective surgery, perhaps by delaying its development, the problem is far from being eradicated. The regulation of the processes involved in PCO is derived from the signals that the cells receive from their environment, including the cells themselves, or other ocular tissues. Of particular interest are Matrix Metalloproteinases (MMPs) which have been shown to contribute significantly to the cellular transition resulting in PCO. The current project focuses on harnessing this biology in order to limit or eradicate PCO associated with cataract surgery by delivery of MMP-inhibitors to any remaining cells. Other potential ophthalmic applications of MMP inhibiting polymers and surfaces such as in corneal wound healing will also be examined.